Aderamastat is under clinical development by Foresee Pharmaceuticals and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aderamastat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aderamastat overview
Aderamastat (FP-025) is under development for the treatment of house dust mite (HDM)-allergic asthma, chronic obstructive pulmonary disease (COPD), interstitial lung diseases and inflammatory bowel disease, cardiac sarcoidosis. It is administered through oral route. The therapeutic candidate is being developed based on stabilized injectable formulation (SIF) platform technology. It acts by selectively targeting MMP-12 enzyme. It was also under development for the treatment of acute lung injury, non-alcoholic steatohepatitis and wound healing.
It was under development for the treatment of covid 19 with associated acute respiratory distress syndrome (ARDS).
Foresee Pharmaceuticals overview
Foresee Pharmaceuticals (FP) is a clinical-stage pharmaceutical company. It focuses on developing drugs for unmet medical needs. The company’s product portfolio comprises FP-001, for prostate cancer, FP-025, for asthma and chronic obstructive pulmonary disease, FP-020, for Alport syndrome and FP-014, for prostate cancer among others. It harnesses the stabilized injectable formulation (SIF) platform technology to develop controlled release drug delivery systems for peptides, small molecules and proteins. The company works in collaboration with ScinoPharm and Pierre Fabre to research and develop its product portfolio. It has an operational presence in Taiwan and the US. FP is headquartered in Taipei, Taiwan.
For a complete picture of Aderamastat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
